ProfileGDS5678 / 1428160_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 50% 55% 55% 54% 57% 53% 59% 54% 55% 54% 55% 59% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3058152
GSM967853U87-EV human glioblastoma xenograft - Control 23.1870550
GSM967854U87-EV human glioblastoma xenograft - Control 33.3645855
GSM967855U87-EV human glioblastoma xenograft - Control 43.3138655
GSM967856U87-EV human glioblastoma xenograft - Control 53.3044154
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5392557
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3957253
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5523159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3318454
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3514255
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.329454
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3266155
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5758259
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3515155